Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02749292 · ClinicalTrials.gov registry record · Phase 4
Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- Phase 4
- Development phase
- 115
- Enrollment target
NCT02749292: Clinical Trial Phase 4 study, sponsored by Massachusetts General Hospital.
NCT02749292 is a Phase 4 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 115 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02749292, a Phase 4 study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 115 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the best management strategy to maintain remission in patients with ANCA vasculitis who have been treated with rituximab induced B cell depletion for at least two years. This study will compare intermittent B Cell depletion upon B cell return or intermittent B cell depletion upon serologic relapse.
Interventions
- DRUG Rituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2016-06 |
| Est. Completion | 2022-01-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02749292
The ClinicalTrials.gov registry entry for NCT02749292 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 115 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rituximab is the first listed.
NCT02749292 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02749292 about?
NCT02749292 is a clinical study titled "Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing". The purpose of this study is to determine the best management strategy to maintain remission in patients with ANCA vasculitis who have been treated with rituximab induced B cell depletion for at least two years. This study will compare intermittent B Cell depletion upon B cell return or intermittent...
What is the current status of trial NCT02749292?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 115 participants. The study started on 2016-06. Estimated completion is 2022-01-31.
What interventions are being tested in trial NCT02749292?
The interventions under investigation include: Rituximab (DRUG).
Who is sponsoring clinical trial NCT02749292?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.